 |
Health
Needs Assessment tool now available as part of the National Diabetes
Information Service |
| |
The Health Needs Assessment tool allows
you to view any PCT's performance in diabetes care against a large
number of indicators. Most fields specified in the NHS Diabetes
commissioning guide are covered within this tool (National Diabetes Information Service, UK) |
| |
|
|
Doctors
warned over common diabetes drug |
| |
A study found that people taking drugs called
sulphonylureas are more likely to have heart attacks, heart failure
or die, compared to people taking another popular diabetes drug
called metformin (Guardian, UK) |
| |
|
|
Risk
of cardiovascular disease and all cause mortality among patients
with type 2 diabetes prescribed oral antidiabetes drugs |
| |
Retrospective cohort study using UK general
practice research database - Our findings suggest a relatively
unfavourable risk profile of sulphonylureas compared with metformin
for all outcomes examined. Pioglitazone was associated with reduced
all cause mortality compared with metformin (BMJ) |
| |
|
|
Long-term
glycaemic effects of pioglitazone compared with placebo as add-on
treatment to metformin or sulphonylurea monotherapy |
| |
Intensifying an existing oral monotherapy regimen
to a dual oral regimen by adding pioglitazone resulted in sustained
improvements in glycaemic control and reduced progression to insulin
therapy. The efficacy and safety of adding pioglitazone to either
metformin monotherapy or sulphonylurea monotherapy were good (Diabetic
Medicine) |
| |
|
|
Primary
Care Diabetes |
| |
Contents for November 2009 (PCD) |
| |
|
|
Are
people with negative diabetes screening tests falsely reassured? |
| |
Parallel group cohort study embedded in the
ADDITION (Cambridge) randomised controlled trial - A negative test
result at diabetes screening does not seem to promote false reassurance,
whether this is expressed as lower perceived risk, lower intentions
for health related behavioural change, or higher self rated health
(BMJ) |
| |
|
|
DIAMAP – mapping
the future of diabetes research |
| |
It may be a surprise to hear that at present
there is no overall plan or framework to coordinate or fund research
into diabetes across Europe – despite the urgent attention called to the disease from many organizations both
patient-led and professional (DIAMAP) |
| |
|
|
Researchers
stop diabetes progression in a clinical trial |
| |
A JDRF-funded clinical trial has shown that
a drug used to treat certain types of cancer can protect beta cells,
and therefore preserve insulin production, in people newly diagnosed
with type 1 diabetes (JDRF) |
| |
|
|
Improving
supported self-management for people with diabetes |
| |
In this document we look at what we consider
are the essential components that make up good supported self-management.
While there are many things that enable people to self-manage,
we have outlined what should be provided at the very least (Diabetes,
UK) |
| |
|
|
Development
and Validation of a Patient Self-assessment Score for Diabetes
Risk |
| |
This easy-to-implement diabetes screening score
seems to demonstrate improvements over existing methods. Studies
are needed to evaluate it in diverse populations in real-world
settings (Annals of Internal Medicine) |
| |
|
|
Smoking
and diabetes—The double health hazard! |
| |
Smoking cessation programs are of great importance
for primary care specialists dealing with diabetes (Primary Care
Diabetes) |
| |
|
|
Abnormal
liver function tests in patients with Type 1 diabetes mellitus:
prevalence, clinical correlations and underlying pathologies |
| |
Patients with Type 1 diabetes and elevated alanine
transaminase should be investigated as significant abnormalities
may be found which are amenable to interventions (Diabetic Medicine) |
| |
|
|
Impact
of Glucose Tolerance Status on Development of Ischemic Stroke
and Coronary Heart Disease |
| |
Our findings suggest that diabetes is an independent
risk factor for ischemic stroke in both sexes and CHD in women
in the Japanese population (Stroke - American Heart Association) |
| |
|
|
Perinatal
risk factors for early onset of Type 1 diabetes in a 2000–2005 birth cohort |
| |
Size-for-gestational-age had a consistent association
with risk of early onset of Type 1 diabetes, small size being protective.
Size-for-gestational-age measures should be preferred to birth
weight thresholds when assessing risk of diabetes (Diabetic Medicine) |
| |
|
|
Study
Finds Generex Oral-lyn(TM) is Safe, Effective, May Reduce Complications
of Insulin-Dependent D |
| |
Published in the journal Diabetes, Obesity and
Metabolism, an independent review of clinical trials of Generex
Oral-lyn(TM) shows that the oral insulin spray has a faster onset
of action and shorter duration of action than insulin delivered
subcutaneously (Generex) |
| |
|
|
Roche’s
diabetes drug tops rival Januvia |
| |
The once-weekly GLP-1 analogue was found to
meet endpoints in trials that compared it to Merck’s Januvia (sitagliptin) and placebo. Indeed, patients taking taspoglutide had
greater HbA1c reductions - a marker of blood glucose levels - than
those on Januvia and placebo after 24 weeks (PharmaTimes) |
| |
|
|
Examination
of all type 2 diabetes GWAS loci reveals HHEX-IDE as a locus
influencing pediatric BMI |
| |
Our data show that the same genetic HHEX-IDE
variant which is associated with type 2 diabetes from previous
studies also influences pediatric BMI (Diabetes) |
| |
|
|
Making
a difference to global diabetes |
| |
President's editorial (Diabetes Voice, IDF) |
| |
|
|
Against
the worldwide epidemic |
| |
Editor-in-chief's editorial (Diabetes Voice,
IDF) |
| |
|
